FONT-SIZE Plus   Neg

MMRC And Synta Pharma Begin Ganetespib Clinical Trial In Multiple Myeloma

Synta Pharmaceuticals Corp. (SNTA) and the Multiple Myeloma Research Consortium or MMRC announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals, as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADE) for the treatment of relapsed multiple myeloma.

The trial, made possible by the funding up to $1 million by the Multiple Myeloma Research Foundation (MMRF), will be conducted through the MMRC. The MMRC is a consortium of sixteen world-renowned academic institutions and community centers whose mission is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Large U.S. companies are holding trillions of dollars overseas in an effort to avoid U.S. taxes, with big-name firms like Apple (AAPL), Pfizer (PFE) and PepsiCo (PEP) named as notable examples. This is the claim made by a pair of non-profit groups, who released a study based on the firms' financial statements. The European Investment Bank or EIB will be examining whether the German auto giant Volkswagen utilized loans from any of the European Union countries to develop the illegal software to evade emissions. If the car maker is a culprit, the Bank will take actions to get back the loan. Mainland reinsurer China Re is set out to reinvigorate the Asian IPO market that went into a lull following the recent market volatility. The reinsurer, which boasts of having 93 percent of the domestic insurers as its clients, is set to list its shares in the Hong Kong market.
comments powered by Disqus
Trade SNTA now with 
Follow RTT